Judah Frommer
Stock Analyst at Morgan Stanley
(4.00)
# 595
Out of 5,044 analysts
182
Total ratings
60.9%
Success rate
7.73%
Average return
Main Sectors:
Stocks Rated by Judah Frommer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABVX ABIVAX Société Anonyme | Maintains: Overweight | $71 → $101 | $94.25 | +7.17% | 3 | Sep 12, 2025 | |
| TRVI Trevi Therapeutics | Initiates: Overweight | $18 | $10.54 | +70.78% | 1 | Aug 21, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Equal-Weight | $25 → $26 | $30.05 | -13.48% | 2 | Jul 2, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Overweight | $46 → $43 | $27.07 | +58.85% | 2 | May 9, 2025 | |
| RGNX REGENXBIO | Maintains: Overweight | $22 → $24 | $13.16 | +82.37% | 2 | Mar 14, 2025 | |
| GLPG Galapagos NV | Downgrades: Underweight | $31 → $22 | $31.31 | -29.73% | 3 | Feb 14, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Underweight | $8 → $6 | $11.96 | -49.83% | 2 | Jan 13, 2025 | |
| ACLX Arcellx | Maintains: Overweight | $81 → $106 | $87.52 | +21.12% | 2 | Nov 6, 2024 | |
| BCAX Bicara Therapeutics | Initiates: Overweight | $35 | $17.08 | +104.92% | 1 | Oct 8, 2024 | |
| MURA Mural Oncology | Initiates: Overweight | $13 | $2.10 | +520.53% | 1 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Equal-Weight | $3 | $3.04 | -1.32% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $40 | $2.34 | +1,609.40% | 8 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $2.29 | +467.69% | 5 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $69.93 | -57.10% | 8 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $23 | $31.63 | -27.28% | 5 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $50 | $67.48 | -25.90% | 9 | Jul 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $141 | $24.22 | +482.16% | 13 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $9 | $5.96 | +51.01% | 5 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $21 → $22 | $36.14 | -39.13% | 2 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $7 | $5.60 | +25.00% | 3 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $8 | $10.00 | -20.00% | 5 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $68.49 | -32.84% | 5 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6.5 → $7 | $3.04 | +130.26% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $51 → $55 | $70.00 | -21.43% | 3 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $165.29 | -72.17% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $49 | $100.13 | -51.06% | 4 | Nov 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $328 → $370 | $924.16 | -59.96% | 2 | Oct 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $31 | $74.31 | -58.28% | 6 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $76 | $75.89 | +0.14% | 8 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $182 | $101.92 | +78.57% | 9 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $107 | $102.70 | +4.19% | 15 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $90 → $95 | $124.43 | -23.65% | 10 | Jul 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $18.47 | -2.54% | 1 | Jul 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $93 → $116 | $160.67 | -27.80% | 15 | Jun 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $38 | $92.42 | -58.88% | 4 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $22 | $106.80 | -79.40% | 1 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $33 → $35 | $67.69 | -48.29% | 9 | Apr 29, 2020 |
ABIVAX Société Anonyme
Sep 12, 2025
Maintains: Overweight
Price Target: $71 → $101
Current: $94.25
Upside: +7.17%
Trevi Therapeutics
Aug 21, 2025
Initiates: Overweight
Price Target: $18
Current: $10.54
Upside: +70.78%
Apellis Pharmaceuticals
Jul 2, 2025
Maintains: Equal-Weight
Price Target: $25 → $26
Current: $30.05
Upside: -13.48%
Celldex Therapeutics
May 9, 2025
Maintains: Overweight
Price Target: $46 → $43
Current: $27.07
Upside: +58.85%
REGENXBIO
Mar 14, 2025
Maintains: Overweight
Price Target: $22 → $24
Current: $13.16
Upside: +82.37%
Galapagos NV
Feb 14, 2025
Downgrades: Underweight
Price Target: $31 → $22
Current: $31.31
Upside: -29.73%
4D Molecular Therapeutics
Jan 13, 2025
Maintains: Underweight
Price Target: $8 → $6
Current: $11.96
Upside: -49.83%
Arcellx
Nov 6, 2024
Maintains: Overweight
Price Target: $81 → $106
Current: $87.52
Upside: +21.12%
Bicara Therapeutics
Oct 8, 2024
Initiates: Overweight
Price Target: $35
Current: $17.08
Upside: +104.92%
Mural Oncology
Apr 4, 2024
Initiates: Overweight
Price Target: $13
Current: $2.10
Upside: +520.53%
Mar 7, 2024
Assumes: Equal-Weight
Price Target: $3
Current: $3.04
Upside: -1.32%
Aug 14, 2023
Reiterates: Outperform
Price Target: $40
Current: $2.34
Upside: +1,609.40%
Aug 9, 2023
Reiterates: Outperform
Price Target: $13
Current: $2.29
Upside: +467.69%
Aug 9, 2023
Reiterates: Outperform
Price Target: $30
Current: $69.93
Upside: -57.10%
Aug 8, 2023
Reiterates: Outperform
Price Target: $23
Current: $31.63
Upside: -27.28%
Jul 20, 2023
Reiterates: Neutral
Price Target: $50
Current: $67.48
Upside: -25.90%
Jun 23, 2023
Reiterates: Neutral
Price Target: $141
Current: $24.22
Upside: +482.16%
May 12, 2023
Reiterates: Outperform
Price Target: $9
Current: $5.96
Upside: +51.01%
Apr 3, 2023
Maintains: Outperform
Price Target: $21 → $22
Current: $36.14
Upside: -39.13%
Mar 31, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $5.60
Upside: +25.00%
Mar 10, 2023
Downgrades: Neutral
Price Target: $11 → $8
Current: $10.00
Upside: -20.00%
Mar 7, 2023
Reiterates: Outperform
Price Target: $46
Current: $68.49
Upside: -32.84%
Mar 7, 2023
Upgrades: Neutral
Price Target: $6.5 → $7
Current: $3.04
Upside: +130.26%
Feb 28, 2023
Maintains: Outperform
Price Target: $51 → $55
Current: $70.00
Upside: -21.43%
Feb 24, 2023
Reiterates: Outperform
Price Target: $46
Current: $165.29
Upside: -72.17%
Nov 5, 2020
Maintains: Outperform
Price Target: $47 → $49
Current: $100.13
Upside: -51.06%
Oct 6, 2020
Maintains: Neutral
Price Target: $328 → $370
Current: $924.16
Upside: -59.96%
Sep 21, 2020
Maintains: Outperform
Price Target: $24 → $31
Current: $74.31
Upside: -58.28%
Sep 21, 2020
Maintains: Outperform
Price Target: $65 → $76
Current: $75.89
Upside: +0.14%
Aug 6, 2020
Assumes: Neutral
Price Target: $182
Current: $101.92
Upside: +78.57%
Aug 6, 2020
Assumes: Outperform
Price Target: $107
Current: $102.70
Upside: +4.19%
Jul 22, 2020
Maintains: Neutral
Price Target: $90 → $95
Current: $124.43
Upside: -23.65%
Jul 21, 2020
Initiates: Outperform
Price Target: $18
Current: $18.47
Upside: -2.54%
Jun 10, 2020
Maintains: Outperform
Price Target: $93 → $116
Current: $160.67
Upside: -27.80%
May 22, 2020
Maintains: Outperform
Price Target: $31 → $38
Current: $92.42
Upside: -58.88%
May 6, 2020
Maintains: Neutral
Price Target: $18 → $22
Current: $106.80
Upside: -79.40%
Apr 29, 2020
Maintains: Neutral
Price Target: $33 → $35
Current: $67.69
Upside: -48.29%